The relationship between target joints and direct resource use in severe haemophilia

Springer Science and Business Media LLC - Tập 8 - Trang 1-7 - 2018
Jamie O’Hara1, Shaun Walsh2, Charlotte Camp2, Giuseppe Mazza3, Liz Carroll4, Christina Hoxer5, Lars Wilkinson5
1Faculty of Health and Social Care, University of Chester, Chester, UK
2HCD Economics, The Innovation Centre, Daresbury, UK
3UCL Institute for Liver and Digestive Health, Royal Free Hospital, University College London, London, UK
4The Haemophilia Society, London, UK
5Novo Nordisk A/S, Søborg, Denmark

Tóm tắt

Target joints are a common complication of severe haemophilia. While factor replacement therapy constitutes the majority of costs in haemophilia, the relationship between target joints and non drug-related direct costs (NDDCs) has not been studied. Data on haemophilia patients without inhibitors was drawn from the ‘Cost of Haemophilia across Europe – a Socioeconomic Survey’ (CHESS) study, a cost assessment in severe haemophilia A and B across five European countries (France, Germany, Italy, Spain, and the United Kingdom) in which 139 haemophilia specialists provided demographic and clinical information for 1285 adult patients. NDDCs were calculated using publicly available cost data, including 12-month ambulatory and secondary care activity: haematologist and other specialist consultant consultations, medical tests and examinations, bleed-related hospital admissions, and payments to professional care providers. A generalized linear model was developed to investigate the relationship between NDDCs and target joints (areas of chronic synovitis), adjusted for patient covariates. Five hundred and thirteen patients (42% of the sample) had no diagnosed target joints; a total of 1376 target joints (range 1–10) were recorded in the remaining 714 patients. Mean adjusted NDDCs for persons with no target joints were EUR 3134 (standard error (SE) EUR 158); for persons with one or more target joints, mean adjusted NDDCs were EUR 3913 (SE EUR 157; average mean effect EUR 779; p < 0.001). Our analysis suggests that the presence of one or more target joints has a significant impact on NDDCs for patients with severe haemophilia, ceteris paribus. Prevention and management of target joints should be an important consideration of managing haemophilia patients.

Tài liệu tham khảo

Liras A, Segovia C, Gabán AS. Advanced therapies for the treatment of hemophilia: future perspectives. Orphanet J. Rare Dis. 2012;7:97. Srivastava A, Brewer AK, Mauser-Bunschoten EP, Key NS, Kitchen S, Llinas A, et al. WFH guidelines: guidelines for the management of hemophilia. Haemophilia. 2013;19:1–47. Lobet S, Hermans C, Lambert C. Optimal management of hemophilic arthropathy and hematomas. J Blood Med Dove Press. 2014;5:207–18. Mulder K, Llinás A. The target joint. Haemophilia. 2004;10(Suppl 4):152–6. Manco-Johnson MJ, Soucie JM, Gill JC. Prophylaxis usage, bleeding rates and joint outcomes of hemophilia 1999 - 2010: a surveillance project. Blood. 2017;129:2368–75. Monahan PE, Baker JR, Riske B, Soucie JM. Physical functioning in boys with hemophilia in the U.S. Am J Prev Med. 2011;41:S360–8. Bladen M, Main E, Hubert N, Koutoumanou E, Liesner R, Khair K. Factors affecting the Haemophilia joint health score in children with severe haemophilia. Haemophilia. 2013;19:626–31. Soucie JM, Wang C, Siddiqi A, Kulkarni R, Recht M, Konkle BA, et al. The longitudinal effect of body adiposity on joint mobility in young males with Haemophilia a. Haemophilia. 2011;17:196–203. Iannone M, Pennick L, Tom A, Cui H, Gilbert M, Weihs K, et al. Prevalence of depression in adults with haemophilia. Haemophilia. 2012;18:868–74. Cassis FRMY, Querol F, Forsyth A, Iorio A, HERO International Advisory. Board. Psychosocial aspects of haemophilia: a systematic review of methodologies and findings. Haemophilia. 2012;18:e101–14. World Federation of Hemophilia. Frequently asked questions about hemophilia [Internet]. 2012 [cited 2015 Jul 31]. Available from: http://www.wfh.org/en/page.aspx?pid=637#Life_expectancy. Johnson KA, Zhou Z-Y. Costs of care in hemophilia and possible implications of health care reform. Hematology am. Soc. Hematol. Educ. Program. 2011;2011:413–8. Henrard S, Hermans C, Devleesschauwer B, Speybroeck N. Oral presentations: abstracts. Eur J Public Health O. 2012;22:10–125. Kodra Y, Cavazza M, Schieppati A, De Santis M, Armeni P, Arcieri R, et al. The social burden and quality of life of patients with haemophilia in Italy. Blood Transfus. SIMTI Servizi; 2014;12 Suppl 3:s567–s575. O’Hara J, Hughes D, Camp C, Burke T, Carroll L. Diego D-AG. The cost of severe haemophilia in Europe: the CHESS study. Orphanet J Rare Dis. 2017;12(1):106. Bohn RLRL, Aledort LM, Putnam K, Ewenstein B, Mogun H, Avorn JJ. The economic impact of factor VIII inhibitors in patients with haemophilia. Haemophilia. 2004;10:63–8. Knight C. Health economics of treating haemophilia a with inhibitors. Haemophilia. 2005;11(Suppl 1):11–7. Konkle BA, Ebbesen LS, Erhardtsen E, Bianco RP, Lissitchkov T, Rusen L, et al. Randomized, prospective clinical trial of recombinant factor VIIa for secondary prophylaxis in hemophilia patients with inhibitors. J Thromb Haemost Blackwell Publishing Ltd. 2007;5:1904–13. Glick HA, Doshi JA, Sonnad SS, Polsky D. Economic Evaluation in Clinical Trials. Oxford University Press; 2014. Mihaylova B, Briggs A, O’Hagan A, Thompson SG. Review of statistical methods for analysing healthcare resources and costs. Health Econ. 2011;20:897–916. Coughlan D, Yeh ST, Neill CO, Frick KD. Evaluating direct medical expenditures estimation methods of adults using the medical expenditure panel survey : an example focusing on head and neck cancer. Value Heal Elsevier. 2014;17:90–7. Stata Statistical Software. College Station: StataCorp; 2013. Blanchette VS, Key NS, Ljung LR, Manco-Johnson MJ, van den Berg HM, Srivastava A, et al. Definitions in hemophilia: communication from the SSC of the ISTH. J Thromb Haemost. 2014;12:1935–9. Price VE, Hawes SA, Chan AK. A practical approach to hemophilia care in children. Paediatr Child Heal. 2007;12:381–3. Donadel-Claeyssens S. European Paediatric network for Haemophilia management. Current co-ordinated activities of the PEDNET (European Paediatric network for Haemophilia management). Haemophilia. 2006;12:124–7. Hanley J, McKernan A, Creagh MD, Classey S, McLaughlin P, Goddard N, et al. Guidelines for the management of acute joint bleeds and chronic synovitis in haemophilia: a United Kingdom Haemophilia Centre doctors’ organisation (UKHCDO) guideline. Haemophilia. 2017;23:511–20.